Innovation During COVID-19: Improving Addiction Treatment Access
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
During the COVID-19 pandemic, many addiction treatment and harm reduction organizations have had to reduce their hours and services for people with substance use disorders, placing these individuals at increased risk of death. In order to address restricted treatment access during COVID-19, guidance from the Substance Abuse Mental Health Services Administration, the US Drug Enforcement Administration, and the US Department of Health and Human Services has allowed for use of audio-only telehealth encounters for buprenorphine induction without requiring an in-person evaluation or video interface. This has enabled innovations in order to try to meet the needs of the most vulnerable among us during the current pandemic. In this new regulatory environment, we established the Rhode Island Buprenorphine Hotline, a phone hotline which functions as a “tele-bridge” clinic where people with moderate to severe opioid use disorder can be linked with a DATA 2000 waivered provider who can provide an initial assessment and, if appropriate, prescribe buprenorphine for unobserved induction and linkage to outpatient treatment. In this correspondence we briefly share our experience developing this common sense approach to addressing the complex problem of access to treatment only now permissible due to regulatory changes during COVID-19.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Cited by
Non-pharmaceutical interventions during the COVID-19 pandemic: A review
Perra, N. (2021) · Physics Reports · doi:10.1016/j.physrep.2021.02.001 · Cited by 531
Philippe, T. J., Sikder, N., Jackson, A., Koblanski, M. E., Liow, E., Pilarinos, A., & Vasarhelyi, K. (2022) · JMIR Mental Health · doi:10.2196/35159 · Cited by 436
Johnson, S., Dalton-Locke, C., Vera San Juan, N., Foye, U., Oram, S., Papamichail, A., Landau, S., Rowan Olive, R., Jeynes, T., Shah, P., et al. (2021) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-020-01927-4 · Cited by 227
Jones, C. M., Houry, D., Han, B., Baldwin, G., Vivolo‐Kantor, A., & Compton, W. M. (2022) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14688 · Cited by 202
Frank, D., Mateu-Gelabert, P., Perlman, D. C., Walters, S. M., Curran, L., & Guarino, H. (2021) · Harm Reduction Journal · doi:10.1186/s12954-021-00535-y · Cited by 180
“Nevertheless, drug user advocates see the expanded access as an opportunity for change, and have pushed to make the new standards permanent [24, 25].”
Background
Metadata
- Authors
- Samuels, E. A., Clark, S. A., Wunsch, C., Jordison Keeler, L. A., Reddy, N., Vanjani, R., & Wightman, R. S.
- Venue
- Journal of Addiction Medicine
- Published
- 2020-05-12
- Volume
- 14
- Issue
- 4
- Pages
- e8-e9
- ISSN
- 1932-0620 (ISSN-L)
- 1935-3227
- OpenAlex
- W3025082979
- Cited by
- 143
- References
- 1
- FWCI
- 21.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Innovation During COVID-19: Improving Addiction Treatment Access. https://app.cochat.ai/papers/10.1097/adm.0000000000000685
- The paper
- Samuels, E. A., Clark, S. A., Wunsch, C., Jordison Keeler, L. A., Reddy, N., Vanjani, R., & Wightman, R. S. (2020). Innovation During COVID-19: Improving Addiction Treatment Access. Journal of Addiction Medicine. https://doi.org/10.1097/adm.0000000000000685
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.